Why Lymphoma Subtype Matters as Much as the Diagnosis
“Lymphoma” is not a single disease. It is a family of cancers with very different behaviors, response rates, and median survival times. The WHO REAL classification (Revised European-American Lymphoma) is the framework that veterinary oncologists use to organize these subtypes, and it has been adopted into the ACVIM-Oncology workflow for both dogs and cats. Two pets with multicentric peripheral lymphadenopathy can sit on opposite ends of the prognosis curve once a board-certified veterinary pathologist (DACVP) returns the WHO REAL subtype.
In this article
- Why Lymphoma Subtype Matters as Much as the Diagnosis
- What WHO REAL Actually Classifies
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
- T-Zone Lymphoma
- Enteropathy-Associated T-Cell Lymphoma (EATL)
- Large Granular Lymphocyte (LGL) and High-Grade Feline GI Lymphoma
- Mediastinal and Nasal Subtypes
- Cytology, Biopsy, and Why Both Often Matter
- Cutaneous Epitheliotropic T-Cell Lymphoma (Mycosis Fungoides Pattern)
- How WHO REAL Shapes Treatment Selection
- Cost and Specialty Access
- How Often the Subtype Changes the Treatment Plan
- Adoption-Positive Framing
- Frequently Asked Questions
This article walks through how the classification is built, the most common subtypes a DACVIM-Oncology team sees in companion animals, and how the immunophenotype changes the conversation about chemotherapy, supportive care, and realistic expectations.
What WHO REAL Actually Classifies
WHO REAL organizes lymphoid neoplasms by three main features: lineage (B-cell, T-cell, or NK/T-cell), anatomic site and pattern (nodal vs extranodal, follicular vs diffuse), and cellular morphology (small, intermediate, or large cell). Each combination has implications for biology, expected response to chemotherapy, and median survival reported in the peer-reviewed literature.
The classification is built from a combination of histopathology on an excisional biopsy, immunohistochemistry (IHC) for surface markers, flow cytometry, and PARR PCR clonality testing. Our companion flow cytometry and PARR PCR guide covers the molecular foundation in depth.
Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL is the most common WHO REAL subtype in dogs and accounts for the majority of multicentric peripheral lymphadenopathy cases. Diagnostic features include large cells, a diffuse pattern, CD20 and CD79a positivity on IHC, and CD21 positivity on flow cytometry. DLBCL is the textbook indication for full Madison-Wisconsin or CHOP-based chemotherapy. Literature median survival times sit around 12 months with full induction, with first remission averaging six months and a wide individual range.
Some DLBCL cases also receive newer biologics such as anti-CD20 monoclonal antibody therapy when available, and Tanovea (rabacfosadine) is an FDA-approved oral agent often considered for B-cell relapse or selected first-line cases. The DACVIM-Oncology specialist factors immunophenotype, anatomic stage, owner goals, and tolerance into the selection between standard CHOP-based induction and these newer alternatives.
Within DLBCL, additional molecular subgroups continue to emerge in research, including activated B-cell-like and germinal-center B-cell-like patterns that may eventually influence treatment selection in companion animals as they already do in human oncology. For now, the practical treatment decision rests on the DLBCL diagnosis itself, the WHO clinical stage, and the patient’s overall health.
Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
PTCL-NOS is the most common T-cell subtype in dogs and shows CD3 positivity with variable CD4 and CD8 patterns. Boxers, Golden Retrievers, and several other breeds are over-represented in the peer-reviewed data. PTCL-NOS typically responds less durably to standard Madison-Wisconsin protocols than DLBCL, with shorter median survival reported in many series.
That shorter response is not a reason to give up. Many T-cell lymphoma patients still achieve meaningful remission with modified protocols that emphasize alkylator drugs such as lomustine, and the DACVIM-Oncology specialist will tailor the approach to the individual.
T-Zone Lymphoma
T-zone lymphoma is an indolent T-cell subtype that often presents with peripheral lymphadenopathy in older dogs, sometimes incidentally. Cells are small to intermediate, CD45-negative, and arise in the T-zone of the lymph node. Median survival can extend two to three years or longer with conservative management, and many oncologists do not initiate aggressive cytotoxic chemotherapy in the absence of clinical signs.
Distinguishing T-zone lymphoma from PTCL-NOS is one of the highest-value contributions of full WHO REAL workup, because the treatment and prognostic conversation differs dramatically.
Enteropathy-Associated T-Cell Lymphoma (EATL)
EATL is the WHO REAL designation for feline small-cell gastrointestinal lymphoma, the most common feline lymphoma in the post-FeLV vaccination era. It is a T-cell process with small lymphocytes that infiltrate the intestinal mucosa and can closely mimic inflammatory bowel disease. Full-thickness intestinal biopsies are often more diagnostic than endoscopic samples.
EATL responds well to prednisolone and chlorambucil, an oral alkylator delivered at home with periodic recheck monitoring. Median survival in published case series often runs 12-24 months with good owner adherence. The feline GI lymphoma small-cell vs large-cell article walks through the full differential.
Large Granular Lymphocyte (LGL) and High-Grade Feline GI Lymphoma
High-grade feline GI lymphoma is most often a large-cell B-cell or T-cell process. Large granular lymphocyte (LGL) lymphoma is an aggressive feline variant with cytoplasmic granules visible on cytology and a poor response to even aggressive CHOP-based therapy. Recognition of LGL on the WHO REAL workup changes the conversation toward palliative-first decision making and quality of life. Reference resources include our large-cell lymphoma in cats overview for adopter-facing context.
The cytologic recognition of granular lymphocytes triggers additional confirmatory immunophenotyping for natural killer cell markers and NK/T-cell origin. The DACVP integrates the cytology with clinical staging, abdominal imaging, and the response to initial supportive care to clarify the prognosis. Owners considering treatment for an LGL diagnosis benefit from an honest conversation about realistic outcomes before committing to intensive chemotherapy.
Mediastinal and Nasal Subtypes
Feline mediastinal lymphoma typically presents as a large anterior thoracic mass, often T-cell and historically FeLV-associated. Cats may show respiratory distress and chylothorax at diagnosis, and the treatment framework is covered in our feline mediastinal lymphoma and chylothorax article.
Nasal NK/T-cell lymphoma is another extranodal site in cats and dogs, often presenting with chronic nasal discharge, sneezing, and facial deformity in advanced cases. Radiation therapy plays an important role for many nasal cases, with modern conformal techniques delivering tumoricidal dose while sparing adjacent ocular and dental structures. The DACVR-RO (board-certified veterinary radiation oncologist) plans the treatment field based on CT imaging and the histologic extent of disease.
Burkitt-like and mediastinal large B-cell variants also occur in companion animals, typically aggressive in behavior and treated with CHOP-based protocols. Each variant has its own published response data and is part of the conversation when the DACVIM-Oncology specialist designs the initial treatment plan.
Cytology, Biopsy, and Why Both Often Matter
Cytology from a fine-needle aspirate can suggest a lymphoma subtype but rarely allows definitive WHO REAL classification. The architecture of the lymph node, including whether the abnormal cells preserve a follicular pattern or completely efface the normal structure, requires intact tissue. That architectural information is one of the most important contributions of an excisional biopsy.
An excisional biopsy of a peripheral lymph node is generally well-tolerated under general anesthesia and allows the DACVP to evaluate architecture, perform IHC, and bank tissue for additional studies. For pets with only retroperitoneal or mediastinal lymphadenopathy, ultrasound-guided or CT-guided needle biopsies serve a similar role with somewhat less tissue yield.
Cutaneous Epitheliotropic T-Cell Lymphoma (Mycosis Fungoides Pattern)
Epitheliotropic cutaneous T-cell lymphoma presents in dogs (and rarely cats) with scaly, depigmented, or ulcerated skin lesions, oral mucosal lesions, and gradual progression. IHC confirms CD3 and CD8 positivity with epidermal infiltration. Lomustine is a commonly used systemic agent, and palliative measures support quality of life as the disease progresses. The DACVIM-Oncology team coordinates dermatology and oncology consultations.
How WHO REAL Shapes Treatment Selection
The WHO REAL subtype influences several decisions. Aggressive B-cell DLBCL typically warrants full induction with Madison-Wisconsin or CHOP. Indolent T-zone disease may be managed conservatively. Small-cell EATL responds to oral chlorambucil and prednisolone. High-grade large-cell feline GI or mediastinal disease justifies CHOP-based therapy with realistic expectations. LGL leans toward early palliative decision making. None of these decisions is automatic, and the DACVIM-Oncology consultation puts the histology, immunophenotype, owner goals, and quality-of-life priorities together.
Cost and Specialty Access
A full WHO REAL workup commonly includes an excisional biopsy, histopathology, IHC for several antibodies, and often flow cytometry and PARR on parallel samples. Costs vary by region and laboratory, but a full diagnostic workup is typically several hundred to a thousand dollars beyond the basic cytology. If a board-certified specialist is not available locally, your primary veterinarian can ship samples to a reference laboratory and consult with a DACVIM-Oncology via telemedicine for treatment planning. Discussing realistic costs early helps families plan ahead, and our treatment cost realism guide sets useful baselines.
Specialty access reality varies enormously across regions. Most major metropolitan areas in the United States have at least one DACVIM-Oncology specialist within reasonable driving distance, often at a private specialty practice, university teaching hospital, or large referral center. Rural regions and smaller markets may not, and telemedicine consultation has become an increasingly common bridge. Your primary veterinarian can coordinate sample collection locally, ship to a reference laboratory, and arrange a telemedicine review with an oncology specialist for treatment planning.
How Often the Subtype Changes the Treatment Plan
In peer-reviewed case series, a meaningful proportion of cases initially classified by cytology as “lymphoma” are reclassified after full WHO REAL workup, sometimes shifting an indolent subtype to recognition of aggressive disease (or vice versa) and changing the recommended protocol. That reclassification rate is one of the strongest arguments for investing in the full workup at diagnosis rather than starting empirical chemotherapy based on cytology alone.
The DACVIM-Oncology specialist routinely tells families that the time invested in accurate classification at the outset usually saves time, cost, and missed opportunity later. A protocol matched to the actual biology is more likely to produce durable response than a protocol selected on incomplete information.
Adoption-Positive Framing
A pet diagnosed with a defined lymphoma subtype, paired with informed adopters or foster families, can have an excellent quality of life. Indolent subtypes like T-zone lymphoma and EATL often mean months to years of normal-feeling life. Even aggressive subtypes respond to induction in most cases and offer meaningful remission. The WHO REAL classification gives adopters the clarity to plan with their DACVIM-Oncology team rather than navigate the unknown.
Frequently Asked Questions
Is WHO REAL the same as the Kiel classification?
No. The Kiel classification was an earlier European framework that classified lymphoma by morphology. WHO REAL is more recent and combines lineage, anatomic pattern, and morphology. Most veterinary oncology centers now use the WHO REAL system, though older references may still mention Kiel.
Do I always need IHC on the biopsy?
For straightforward DLBCL with classic cytology and flow cytometry, IHC may be optional in some practices. For low-grade, extranodal, or atypical presentations, IHC is often essential. The DACVIM-Oncology and DACVP team decide together based on the clinical picture.
Why is T-cell lymphoma generally a worse prognosis?
Several T-cell subtypes respond less durably to standard CHOP-based induction than B-cell DLBCL. The biology is different, and treatment optimization is an active area of veterinary oncology research. Indolent T-cell subtypes like T-zone lymphoma are an important exception with relatively long survival.
Can the WHO REAL subtype change over time?
The underlying disease can transform, and an indolent subtype occasionally progresses to a more aggressive form. Recheck biopsies are sometimes recommended at relapse to confirm the current biology guiding rescue therapy.
Where can I learn about specific treatment protocols?
The Madison-Wisconsin protocol article covers the most common induction regimen for canine DLBCL. Your DACVIM-Oncology specialist will tailor the protocol to the WHO REAL subtype and your pet’s specific clinical picture.